The Cardiovascular Genome Phenome Study (CVGPS) is a collaborative effort, spearheaded by the American Heart Association (AHA), to accelerate the future of cardiovascular medicine. CVGPS combines the power of long-term population studies with the precision of molecular analysis to unravel key distinctions between and within subgroups of patients. The discoveries it generates will point the way toward better-targeted, safer, and more effective treatments, based on a deeper understanding of patients’ characteristics, including e.g. risk profiles and therapeutic needs.

The CVGPS is a collaboration among AHA, Boston University (BU) and the University of Mississippi Medical Center (UMMC), the academic coordinating center homes, respectively, of the Framingham Heart Study (FHS) and the Jackson Heart Study (JHS). The Jackson Heart Study also involves Jackson State University (JSU) and Tougaloo College (TC) as partner institutions.

Through the rich diversity of constituent participant/patient populations, CVGPS research will bring inter-individual and patient-to-patient differences into ever sharper focus for common diseases such as atherosclerosis and hypertension.

To accomplish the promise of the CVGPS, AHA is offering the CVGPS Grand Challenge Award, which is funded at $500K/year for 4 years for a total of $2MM. AHA will award one Grand Challenge Award this year.

The Letter of Intent for the Grand Challenge Award is due October 1, 2014. The letter should be sent electronically via email to the American Heart Association at deb.korns@heart.org with a subject of Grand Challenge Award LOI.

The full application will be available on October 6, 2014 and will have a deadline of December 2, 2014. This is a modification of the timeline previously announced in the Request for Applications.

View more details regarding the CVGPS Grand Challenge Award Letter of Intent.

For additional information about the desired characteristics and peer review criteria view the full Request for Applications.